Buy Idhifa (Enasidenib) 100 mg | Best Online Medicine Shop

0.00$

Idhifa (Enasidenib) 100 mg is a medication primarily prescribed for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with specific genetic mutations. It belongs to a class of drugs known as isocitrate dehydrogenase 2 (IDH2) inhibitors, which target mutated IDH2 enzymes found in certain leukemias. By inhibiting these mutated enzymes, Enacitib helps to restore normal cellular differentiation and reduce the proliferation of leukemia cells, thereby improving outcomes for patients with AML.

Here is a table summarizing the details of Enasidenib (Idhifa):

Attribute Details
Dose 100 mg orally once daily
Brand Name Idhifa
Generic Name Enasidenib
Producer Celgene Corporation
Made In Manufactured in the United States
Indication Relapsed or refractory AML with IDH2 mutation
Administration Oral
Common Side Effects Nausea, vomiting, diarrhea, jaundice, elevated bilirubin, decreased appetite, electrolyte imbalances
Monitoring CBCs, liver function tests, electrolytes, signs of differentiation syndrome
Warnings Differentiation syndrome, hepatotoxicity, tumor lysis syndrome
Contraindications None known, caution in severe hepatic impairment
Pregnancy Category May cause fetal harm, effective contraception required
Breastfeeding Not recommended
Drug Interactions Caution with UGT1A1 inducers/inhibitors
Add to wishlist
Share

    Buy Idhifa (Enasidenib) 100 mg

    Buy Idhifa (Enasidenib) 100 mg : Enasidenib, sold under the brand name Idhifa, is a medication used to treat certain types of acute myeloid leukemia (AML). Idhifa is specifically indicated for the treatment of adult patients with relapsed or refractory AML who have an isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test.

    Here are some key details about Enasidenib (Idhifa):

    Mechanism of Action of Buy Idhifa (Enasidenib) 100 mg:

    Enasidenib is an inhibitor of the IDH2 enzyme. Mutations in the IDH2 gene result in the production of an abnormal enzyme that produces 2-hydroxyglutarate (2-HG), which contributes to the development of cancer. By inhibiting this enzyme, enasidenib reduces the levels of 2-HG, helping to restore normal cellular differentiation.

    Dosage of  Idhifa (Enasidenib) 100 mg

    • The recommended dosage of Enasidenib is 100 mg orally once daily, with or without food.
    • The treatment should continue until disease progression.

    Administration:

    • Enasidenib should be swallowed whole and not split or crushed.
    • Patients should be advised to take the medication at the same time each day.

    Side Effects:

    Common side effects of enasidenib include:

    • Nausea
    • Vomiting
    • Diarrhea
    • Jaundice
    • Elevated bilirubin levels
    • Decreased appetite
    • Electrolyte imbalances

    Monitoring:

    Patients taking enasidenib should be monitored regularly for:

    • Complete blood counts (CBCs)
    • Blood chemistry, which includes liver function tests and electrolyte levels.
    • Signs and symptoms of differentiation syndrome (a potentially serious complication)

    Warnings and Precautions:

    • Differentiation Syndrome: A potentially life-threatening complication characterized by fever, dyspnea, acute respiratory distress, and organ dysfunction. It requires prompt treatment with corticosteroids.
    • Hepatotoxicity: Monitor liver function tests prior to and throughout the course of treatment.
    • Tumor Lysis Syndrome (TLS): Patients with high tumor burden are at risk for TLS, which should be managed according to standard medical practices.

    Contraindications:

    • There are no known contraindications to enasidenib; however, it should be used with caution in patients with severe hepatic impairment.

    Drug Interactions:

    • Enasidenib is metabolized by the liver enzyme UGT1A1. Caution should be exercised when co-administering drugs that are strong inducers or inhibitors of this enzyme.

    Use in Specific Populations:

    • Pregnancy and Lactation: Enasidenib may cause fetal harm when administered to a pregnant woman. Women capable of bearing children should use reliable contraception while undergoing treatment and for at least one month after the final dose. Breastfeeding is not recommended during treatment.

    Conclusion:

    Enasidenib (Idhifa) is a targeted therapy for AML patients with an IDH2 mutation, offering a new avenue for treatment in a patient population with limited options. Proper monitoring and management of side effects are crucial for the safe use of this medication. Always consult with a healthcare provider for personalized medical advice.

    Generic Name:

    Enasidenib

    Theraputic Category:

    Anti-Cancer

    Pack Size:

    30’s